Reproducible and scalable human intestine platform for ADME-Tox, DMPK & IBD studies
Testing PGP-mediated Efflux in RepliGut® Planar vs Caco-2
Screen compounds for drug-induced GI toxicity earlier in development.
Evaluate pro- and anti- inflammatory effects of new modalities.
Broaden bioavailability insights compared to Caco-2 cells.
Characterize barrier integrity in response to challenges.
Book today a discovery call to discuss costs and feasibility
How we can help you getting your research from good to great
We are a small but experienced team, and take every project individually from the first to the last step
We believe that “possible” is defined by the amount of energy invested. For your priority projects, you need a reliable partner going the extra mile.
Project failure is not an option. If anything happens during the project, we restart at no extra cost and without delay.
Altis Biosystems has pioneered the creation of Repligut® Systems, a collection of in vitro models derived from stem cells and designed specifically for pre-clinical drug discovery. RepliGut® models are designed to replicate the complex structure of the human small intestine and colonic epithelium using a standard user friendly format.
RepliGut models deliver valuable data insights, rapid screening capabilities, and an unparalleled biobank of ethically sourced donor intestinal cells, paving the way for more effective compound screening, disease modeling, and microbiome research.
RepliGut® Planar kits can include stem cells from any one of 5 distinct intestinal regions. They are all available in 12-well or 96-well transwell plates.
The Stem Cells isolated from the crypts are seeded on the cell culture inserts and expanded for 5 days until confluence. Afterwards the medium is changed to a differentiation medium and cells start polarizing and differentiating for the following 5 days. During the maturation phase, cells form a tight barrier, produce mucus, differentiate in enterocytes/goblet cells/enteroendocrine cells and express characteristic markers.
No drug is born equal, and every project is different. Our team have supported dozens of projects and takes pride in supporting each researcher in their work as they would expect from a colleague.
We sign an NDA and make sure we have clarity on goals, budget and timelines. You want to get results soon, we are here to make this happen.
With a pilot study you can collect the first results and flexibly evaluate the next steps. Our team will support you in drafting the study and finding the most flexible and cost effective solution.
Once the first results are in, you’ll need a reliable partner. Sellomics will help you scale your research and offer a partnership approach to long-term studies that ensures you meet milestones in time and on budget.
Discover the Latest Updates on Our Current Projects and Explore Exciting New Opportunities for Optimizing Efficiency. Subscribe to Our Newsletter and Stay Ahead!
We help Pharma & Biotechs accerlerate their R&D projects with innovative research tools and services.
CEO: Davide Confalonieri, PhD
Amtsgericht Nürnberg
HBR 43057
VAT ID: DE367624510
Copyright 2024 © All Rights reserved by Sellomics GmbH
Made with ❤ by Konstanz-Marketing.de